Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression

Journal of Human Genetics

Volumn 54, Issue 10, 2009, Pages 572-580

  Cha, Pei Chieng ^a   Mushiroda, Taisei ^b   Zembutsu, Hitoshi ^a   Harada, Hiromasa ^c   Shinoda, Noriyuki ^c   Kawamoto, Shunji ^c   Shimoyama, Rai ^c   Nishidate, Toshihiko ^d   Furuhata, Tomohisa ^d   Sasaki, Kazuaki ^d   Hirata, Koichi ^d   Nakamura, Yusuke ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b RIKEN   (Japan)

^c Tokushukai Group   (Japan)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ABCG2; Adverse drug reaction; Irinotecan; Myelosuppression; SNP

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; IRINOTECAN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CASE CONTROL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG METABOLISM; DRUG TRANSPORT; ESOPHAGUS CANCER; FEMALE; GENE MAPPING; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; JAPANESE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PANCREAS CANCER; PROMOTER REGION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; SYSTEMIC CIRCULATION; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BONE MARROW CELLS; CAMPTOTHECIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNE TOLERANCE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 70350455706     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1038/jhg.2009.80     Document Type: Article

References (42)

1. Pfizer. Full prescription information for Camptosar. Available from URL:http://www. pfizer.com/files/products/uspi-camptosar.pdf.
2. Rothenberg, M. L. Irinotecan (CPT-11): recent developments and future directionscolorectal cancer and beyond. The Oncologist 6, 66-80 (2001).
3. Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S. & Rustum, Y. M. Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol. 19, 1501-1518 (2001). (Pubitemid 32202559)
4. Mathijssen, R. H., Verweij, J., de Jonge, M. J., Nooter, K., Stoter, G. & Sparreboom, A. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J. Clin. Oncol. 20, 81-87 (2002).
5. De Jong, F. A., De Jonge, M. J., Verweij, J. & Mathijssen, R. H. Role of pharmacogenetics in irinotecan therapy. Cancer Lett. 234, 90-106 (2006).
6. Chabot, G. G. Clinical pharmacokinetics of irinotecan. Clin. Pharmacokinet. 33, 245-259 (1997).
7. Cersosimo, R. J. Irinotecan: a new antineoplastic agent for the management of colorectal cancer. Ann. Pharmacother. 32, 1324-1333 (1998).
8. Canal, P., Gay, C., Dezeuze, A., Douillard, J. Y., Bugat, R., Brunet, R. et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 14, 2688-2695 (1996).
9. Saliba, F., Hagipantelli, R., Misset, J. L., Bastian, G., Vassal, G., Bonnay, M. et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J. Clin. Oncol. 16, 2745-2751 (1998).
10. Michael, M., Brittain, M., Nagai, J., Feld, R., Hedley, D., Oza, A. et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J. Clin. Oncol. 22, 4410-4417 (2004).
11. Han, J. Y., Lim, H. S., Yoo, Y. K., Shin, E. S., Park, Y. H., Lee, S. Y. et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110, 138-147 (2007).
12. Rosner, G. L., Panetta, J. C., Innocenti, F. & Ratain, M. J. Pharmacogenetic pathway analysis of irinotecan. Clin. Pharmacol. Ther. 84, 393-402 (2008).
13. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H. & Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51, 4187-4191 (1991).
14. Rivory, L. P., Riou, J., Haaz, M. C., Sable, S., Vuilhorgne, M., Commercon, A. et al. Identification and properties of a major plasma metabolite of Irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res. 56, 1689-1694 (1996).
15. Dodds, H. M., Haaz, M. C., Riou, J. F., Robert, J. & Rivory, L. P. Identification of a new metabolite of CPT-11 (Irinotecan): pharmacological roperties andactivation to SN-38. J. Pharmacol. Exp. Ther. 286, 578-583 (1998).
16. Atsumi, R., Suzuki, W. & Hakusui, H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21, 1159-1169 (1991).
17. Lokiec, F., du Sorbier, B. M. & Sanderink, G. J. Irinotecan (CPT-11) metabolites in human bile and urine. Clin. Cancer Res. 2, 1943-1949 (1996).
18. Michael, M., Thompson, M., Hicks, R. J., Mitchell, P. L., Ellis, A., Milner, A. D. et al. Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. J. Clin. Oncol. 24, 4228-4235 (2006).
19. Innocenti, F., Undevia, S. D., Iyer, L., Chen, P. X., Das, S., Kocherginsky, M. et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388 (2004).
20. Han, J. Y., Lim, H. S., Shin, E. S., Yoo, Y. K., Park, Y. H., Lee, J. E. et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24, 2237-2244 (2006).
21. Smith, N. F., Figg, W. D. & Sparreboom, A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol. In Vitro 20, 163-175 (2006).
22. De Jong, F. A., Scott-Horton, T. J., Kroetz, D. L., McLeod, H. L., Friberg, L. E., Mathijssen, R. H. et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin. Pharmacol. Ther. 81, 42-49 (2007).
23. Takane, H., Miyata, M., Burioka, N., Kurai, J., Fukuoka, Y., Suyama, H. et al. Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther. Drug Monit. 29, 666-668 (2007).
24. Pharmacogenomics Knowledge Base (PharmGKBr). Irinotecan pathway (Liver cell). Available from URL: http://www.pharmgkb.org/do/serve?objId=PA2001.
25. Azrak, R. G., Yu, J., Pendyala, L., Smith, P. F., Cao, S., Li, X. et al. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors. Mol. Cancer Ther. 4, 843-854 (2005).
26. Kim, T. W. & Innocenti, F. Insights, challenges, and future directions in irinogenetics. Ther. Drug Monit. 29, 265-270 (2007).
27. Skol, A. D., Scott, L. J., Abecasis, G. R. & Boehnke, M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat. Genet. 38, 209-213 (2006).
28. National Cancer Institute. Common Toxicity Criteria version 2.0. Available from URL: http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm#ctc-archive.
29. The Leading Project for Personalized Medicine. Available from URL: http://biobankjp.org/.
30. Ohnishi, Y., Tanaka, T., Ozaki, K., Yamada, R., Suzuki, H. & Nakamura, Y. A highthroughput SNP typing system for genome-wide association studies. J. Hum. Genet. 46, 471-477 (2001).
31. Cha, P. C., Mushiroda, T., Takahashi, A., Saito, S., Shimomura, H., Suzuki, T. et al. High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population. J. Hum. Genet. 52, 856-864 (2007).
32. Weir, B. S. Genetic Data Analysis II: Methods for Discrete Population Genetic Data (Sinauer Associates, Inc.: Canada, 1996).
33. Barret, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
34. Robert, J. & Rivory, L. Pharmacology of irinotecan. Drugs Today (Barc) 34, 777-803 (1998).
35. Kawabata, S., Oka, M., Shiozawa, K., Tsukamoto, K., Nakatomi, K., Soda, H. et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem. Biophys. Res. Commun. 280, 1216-1223 (2001).
36. Bates, S. E., Medina-Pérez, W. Y., Kohlhagen, G., Antony, S., Nadjem, T., Robey, R. W. et al. ABCG2 mediates differential resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and homocamptothecins. J. Pharmacol. Exp. Ther. 310, 836-842 (2004).
37. Candeil, L., Gourdier, I., Peyron, D., Vezzio, N., Copois, V., Bibeau, F. et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int. J. Cancer 109, 848-854 (2004).
38. Bessho, Y., Oguri, T., Achiwa, H., Muramatsu, H., Maeda, H., Niimi, T. et al. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer. Cancer Sci. 97, 192-198 (2006).
39. Poonkuzhali, B., Lamba, J., Strom, S., Sparreboom, A., Thummel, K., Watkins, P. et al. Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab. Dispos. 36, 780-795 (2008).
40. Ciotti, M., Basu, N., Brangi, M. & Owens, I. S. Glucuronidation of 7-ethyl-10- hydroxycamptothecin (SN-38) by the human UDP- glucuronosyltransferases encoded at the UGT1 locus. Biochem. Biophys. Res. Commun. 260, 199-202 (1999).
41. Lankisch, T. O., Vogel, A., Eilermann, S., Fiebeler, A., Krone, B., Barut, A. et al. Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol. Pharmacol. 67, 1732-1739 (2005).
42. Saeki, M., Saito, Y., Jinno, H., Sai, K., Ozawa, S., Kurose, K. et al. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J. 6, 63-75 (2006).